Schrödinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Schrödinger, Inc. (NASDAQ:SDGR) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $32.90.

Separately, BMO Capital Markets increased their target price on shares of Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th.

Schrödinger Stock Performance

NASDAQ SDGR opened at $19.29 on Friday. The firm’s 50 day moving average price is $20.40 and its 200-day moving average price is $20.00. Schrödinger has a 52-week low of $16.67 and a 52-week high of $33.63. The company has a market cap of $1.41 billion, a PE ratio of -8.24 and a beta of 1.59.

Schrödinger (NASDAQ:SDGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $35.30 million for the quarter, compared to analysts’ expectations of $41.25 million. During the same period in the previous year, the company earned ($0.86) EPS. The company’s revenue was down 17.1% on a year-over-year basis. On average, analysts forecast that Schrödinger will post -2.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Margaret Dugan sold 1,531 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the completion of the sale, the insider now owns 13,469 shares of the company’s stock, valued at $239,478.82. The trade was a 10.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 8.60% of the company’s stock.

Institutional Trading of Schrödinger

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP lifted its holdings in shares of Schrödinger by 17.7% in the 3rd quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock worth $68,366,000 after acquiring an additional 555,503 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Schrödinger by 1.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock worth $40,644,000 after acquiring an additional 29,920 shares during the last quarter. State Street Corp lifted its holdings in Schrödinger by 1.8% during the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock worth $39,987,000 after buying an additional 38,972 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Schrödinger by 58.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company’s stock worth $36,083,000 after buying an additional 717,059 shares in the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in Schrödinger by 39.6% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company’s stock worth $28,565,000 after buying an additional 436,789 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.